An Early Phase 1 interventional study of Indomethacin and Placebo in Metabolic Syndrome, sponsored by University of Wisconsin, Madison. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University of Wisconsin, Madison · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 578 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.
Among the 578 studies in Metabolic Syndrome with a site in United States, this one is the 173rd largest by planned enrollment of the 490 interventional ones that give a count, is one of 17 that started in 2026, is one of 23 in phase 1, reaches primary completion later than 75 of the 82 other live ones, and was the 560th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →62 of the 578 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:
Arizona State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
Northwell Health · Sites in United States
Ages 21–75
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
University of Virginia · Sites in United States
Ages 6–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
578 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 68 · Phase 3 20 · Phase 4 44
First in 1982; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 48 across the 490 interventional studies, 141 across the 86 observational. Of the 443 that completed or were terminated, 136 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 578 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 3 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
28 of the studies in Metabolic Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07625332Phase 3Northwell HealthPilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) | 2027-08 |
| NCT07095426Ball State UniversityImpact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes | 2026-11 |
| NCT04974554Medical University of South CarolinaFIT Families Multicomponent Obesity Intervention for African American Adolescents | 2026-11-30 |
| NCT05943626University of UtahCircadian Intervention to Improve Cardiometabolic Health | 2026-12 |
| NCT05654142University of Illinois at ChicagoThe PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older | 2026-12-31 |
Add all 28 to your calendar (.ics) → With an account.
Among the 578 studies in Metabolic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Healthy Controls versus participants with MetSyn.
The central hypothesis is that MetSyn decreases CBF more in females than males due in part to the sex-specific loss of COX vasodilation. This hypothesis is based on extensive preliminary data demonstrating MetSyn induces: 1) 3-fold larger reductions in CBF in females that abolish sex differences, 2) region-specific CBF reduction patterns, and 3) a greater loss of COX-mediated vasodilation in females.
This hypothesis is tested via three Specific Aims:
All consented participants will conduct a screening visit with a blood panel to identify control vs MetSyn eligibility.
Once eligible, participants complete three laboratory visits (each lasting about 2 hours):
Inclusion Criteria (Healthy Controls):
Inclusion Criteria (Participants with Metabolic Syndrome):
Meet at least 3 of the 5 ATP MetSyn criteria. These are:
Exclusion Criteria (Healthy Controls):
Exclusion Criteria (all participants):
Current diagnosis or history of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male and female participants 18-45 without Metabolic Syndrome. On study for 3 visits (up to 6 months). Randomized to either Placebo then Indomethacin or Indomethacin then Placebo for 2 MRI visits.
Drug: Indomethacin · Drug: Placebo · Diagnostic Test: MRI
Male and female participants, age-matched with Healthy Controls, who have at least 3 defining symptoms of Metabolic Syndrome. Randomized to either Placebo then Indomethacin or Indomethacin then Placebo for 2 MRI visits.
Drug: Indomethacin · Drug: Placebo · Diagnostic Test: MRI
Indomethacin is a nonsteroidal anti-inflammatory. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. Indomethacin (1.5 mg/kg) will be taken orally prior to one MRI study visit.
Also known as: Indo
Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit.
Also known as: Lactose
CBF testing will be performed on 3T MRI scanners (GE Healthcare)
Also known as: Magnetic Resonance Imaging
Cerebral Blood Flow
Data collected via MRI under one of 2 conditions: placebo or indomethacin.
Time frame: data collected over 2 study visits that must be completed within 6 months
Cardiorespiratory Fitness: VO2 max
Graded exercise test to assess maximal aerobic capacity, reported as VO2 max (milliliters of oxygen consumed per kilogram of body weight per minute)
Time frame: data collected at one study visit (must be completed within 6 months)
Body Fat Mass
Dual-energy x-ray absorptiometry (DEXA) to measure fat mass.
Time frame: data collected at one study visit (must be completed within 6 months)
Cognitive Testing: Flanker Inhibitory Control and Attention
NIH Toolbox to assess neurocognitive function. The Flanker test is a measure of executive function and is scored using a T-score where 100 is the average, higher scores indicate better performance.
Time frame: data collected at one study visit (must be completed within 6 months)
Cognitive Testing: Pattern Comparison Processing Speed Test
NIH Toolbox to assess neurocognitive function. The Pattern Comparison Processing Speed Test measures how many correct responses the participant has within 90 seconds. There is a maximum of 130 items.
Time frame: data collected at one study visit (must be completed within 6 months)
Cognitive Testing: List Sorting Working Memory Test
NIH Toolbox to assess neurocognitive function. The List Sorting Working Memory Test is a measure of recall and sorting. Participants scores reflect the number of items recalled and appropriately sorted up to 28 items maximum.
Time frame: data collected at one study visit (must be completed within 6 months)
Cognitive Testing: Dimensional Change Card Sort Test
NIH Toolbox to assess neurocognitive function. The Dimensional Change Card Sort Test measures accuracy: the number of accurate responses, up to a maximum of 40.
Time frame: data collected at one study visit (must be completed within 6 months)
Cognitive Testing: Picture Vocabulary Test
NIH Toolbox to assess neurocognitive function. The Picture Vocabulary Test has the participant hear a word and then pick from one of four pictures that best represents the word. It is scored using a T-score where 100 is the average, higher scores indicate better performance.
Time frame: data collected at one study visit (must be completed within 6 months)
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jul 2031, 56 months later.
Of 17 phase 1 interventional studies under Metabolic Syndrome, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 53. This study's planned 56 months is above that.
Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Indomethacin
University of Wisconsin, Madison →